C
Charles A. Coltman
Researcher at University of Texas at San Antonio
Publications - 60
Citations - 5600
Charles A. Coltman is an academic researcher from University of Texas at San Antonio. The author has contributed to research in topics: Prostate Cancer Prevention Trial & Vincristine. The author has an hindex of 31, co-authored 60 publications receiving 5460 citations.
Papers
More filters
Journal ArticleDOI
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
Ian M. Thompson,Donna K. Pauler,Phyllis J. Goodman,Catherine M. Tangen,M. Scott Lucia,Howard L. Parnes,Lori M. Minasian,Leslie G. Ford,Scott M. Lippman,E. David Crawford,John Crowley,Charles A. Coltman +11 more
TL;DR: Biopsy-detected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng per milliliter or less--levels generally thought to be in the normal range.
COMMENTARY Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Scott M. Lippman,Phyllis J. Goodman,Eric A. Klein,Howard L. Parnes,Alan R. Kristal,Regina M. Santella,Jeffrey L. Probstfield,Carol M. Moinpour,Demetrius Albanes,Philip R. Taylor,Lori M. Minasian,Ashraful Hoque,Sarah Moody Thomas,J J. Crowley,J. Michael Gaziano,Janet L. Stanford,Elise D. Cook,Neil Fleshner,Michael M. Lieber,J. Walther,Fadlo R. Khuri,Daniel D. Karp,Gary G. Schwartz,Leslie G. Ford,Charles A. Coltman +24 more
TL;DR: The design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm are discussed.
Journal ArticleDOI
Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.
Bruce W. Dana,Steve Dahlberg,Bharat N. Nathwani,Ellen M. Chase,Charles A. Coltman,Thomas P. Miller,Richard I. Fisher +6 more
TL;DR: Doxorubicin-containing treatment did not prolong the overall median survival of low-grade lymphoma patients compared with results with less-aggressive programs, and histology, age, and sex to be independent predictors of survival.
Journal ArticleDOI
Finasteride Does Not Increase the Risk of High-grade Prostate Cancer: A Bias-adjusted Modeling Approach
Mary W. Redman,Catherine M. Tangen,Phyllis J. Goodman,M. Scott Lucia,Charles A. Coltman,Ian M. Thompson +5 more
TL;DR: The collective results suggest that the observed, unadjusted higher risk of high-grade disease with finasteride seems to have been due to facilitated diagnosis resulting primarily from increased biopsy sensitivity withfinasteride.
Journal ArticleDOI
Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma.
James K. Luce,Jess F. Gamble,Henry E. Wilson,Raymond W. Monto,Bertha L. Isaacs,Robert L. Palmer,Charles A. Coltman,James S. Hewlett,Edmund A. Gehan,Emil Frei +9 more
TL;DR: The survival of patients with lymphosarcoma or reticulum cell sarcoma receiving COP treatment was significantly superior to a comparable group of patients treated sequentially with single agents.